DHS 115.03(1)(1) “Congenital disorder” means a disorder present at birth, either inherited or due to an influence occurring during gestation up to birth. DHS 115.03(2)(2) “Department” means the Wisconsin department of health services. DHS 115.03(3)(3) “ICD-10-CM” means the International Classification of Diseases, 10th Revision, Clinical Modification. DHS 115.03(4)(4) “Medical consultant” means a physician licensed to practice medicine or osteopathy under ch. 448, Stats., who has expertise in treatment of one or more of the conditions listed under s. DHS 115.04. DHS 115.03(5)(5) “Metabolic disorder” means a disorder of the chemical processes that take place in the body. DHS 115.03(6)(6) “Screening” means checking each member of a population to identify presumptive medical conditions that indicate that diagnostic testing for congenital or metabolic disorders is needed. DHS 115.03 HistoryHistory: Cr. Register, May, 1993, No. 449, eff. 6-1-93; correction in (2) made under s. 13.92 (4) (b) 6., Stats., Register January 2009 No. 637; CR 14-074: am. (3) Register July 2015 No. 715, eff. 10-1-15. DHS 115.04DHS 115.04 Congenital disorders. Pursuant to s. 253.13 (1), Stats., blood samples taken from each newborn shall be tested for all of the following conditions: DHS 115.04(4)(4) Hemoglobinopathies, including all of the following: DHS 115.04(6)(6) Congenital adrenal hyperplasia, ICD-10-CM-E25.0. DHS 115.04(8)(8) Fatty acid oxidation disorders, including all of the following: DHS 115.04(8)(a)(a) Medium-chain acyl-CoA dehydrogenase deficiency, ICD-10-CM-E71.311. DHS 115.04(8)(b)(b) Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(c)(c) Very long-chain acyl-CoA dehydrogenase deficiency, ICD-10-CM-E71.310. DHS 115.04(8)(cm)(cm) Carnitine palmitoyltransferase IA deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(d)(d) Carnitine palmitoyltransferase II deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(e)(e) Carnitine-acylcarnitine translocase deficiency, ICD-10-CM-E71.318.